Volta Labs Brings the Complete Twist Hybrid Capture Portfolio to Callisto™ with Launch of Twist Fast Hyb

Impact · against what's priced in

The partnership between Twist Bioscience and Volta Labs marginally increases TWST's accessibility by automating a complex workflow, potentially boosting consumable adoption. While positive, it is an incremental ecosystem expansion rather than a fundamental shift in the company's growth trajectory.

TWST+0.30: No priced-in read yet

Volta Labs Brings the Complete Twist Hybrid Capture Portfolio to Callisto™ with Launch of Twist Fast Hyb

What matters in this story

2 healthcare stocks to turn $10 into $100 by next year

Volta Labs Brings the Complete Twist Hybrid Capture Portfolio to Callisto™ with Launch of Twist Fast Hyb

What matters in this story

2 healthcare stocks to turn $10 into $100 by next year

How each ticker is affected

Track these names every morning.

TransMedics: 2027 Setting Up To Be A Pivotal Year

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline

Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho

Volta Labs Brings the Complete Twist Hybrid Capture Portfolio to Callisto™ with Launch of Twist Fast Hyb

What matters in this story

Next reads from the same story arc

2 healthcare stocks to turn $10 into $100 by next year

Volta Labs Brings the Complete Twist Hybrid Capture Portfolio to Callisto™ with Launch of Twist Fast Hyb

What matters in this story

Next reads from the same story arc

2 healthcare stocks to turn $10 into $100 by next year

How each ticker is affected

Track these names every morning.

TransMedics: 2027 Setting Up To Be A Pivotal Year

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline

Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho